Studies have shown that ultrasound radiomics is expected to be a new imaging label for identifying molecular subtypes (HER2+, triple-negative, Luminal A and Luminal B) of BC patients because of its good performance (38, 39). This evidence concerns the gene ERBB2 and breast cancer.